Company / Operating Income
Tvardi Therapeutics, Inc. Operating Income History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
-$87.5M
FY2024
5-year range
-$111.7M / $5.4M
FY2020-FY2024
Trend
+1.7%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income has fluctuated over the past 10 years, ranging from -$112M in FY2021 to $5M in FY2022.
Based on SEC 10-K filings.
-$88M in FY2024.
Declined from $5M to -$88M over the past 2 years.
Operating Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, operating income increased 1.7% year-over-year.
- Peak operating income was recorded in FY2022.
- Lowest operating income in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -6.41 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$87.5M | +1.7% |
| FY2023 | -$89.1M | -1754.3% |
| FY2022 | $5.4M | +104.8% |
| FY2021 | -$111.7M | -44.3% |
| FY2020 | -$77.4M | -30.1% |
| FY2019 | -$59.5M | -1.9% |
| FY2018 | -$58.4M | -131.9% |
| FY2017 | -$25.2M | -39.4% |
| FY2016 | -$18.1M | -7525.3% |
| FY2015 | -$237.0K | +96.2% |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026